Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report) shares traded down 1.7% during mid-day trading on Wednesday . The company traded as low as $8.14 and last traded at $8.19. 1,235,305 shares traded hands during mid-day trading, an increase of 266% from the average session volume of 337,931 shares. The stock had previously closed at $8.33.
Silverback Therapeutics Stock Down 2.7%
The firm has a fifty day simple moving average of $8.72 and a 200-day simple moving average of $9.21. The company has a market cap of $284.14 million, a PE ratio of -3.26 and a beta of 0.60.
About Silverback Therapeutics
Silverback Therapeutics, Inc (NASDAQ: SBTX) is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company’s proprietary ImmunoTAC™ (tumor-activated cytokine) platform is designed to harness the innate immune system by conjugating toll-like receptor agonists to tumor-targeting antibodies. This modular approach aims to deliver immune-activating molecules directly to the tumor microenvironment, potentially improving the safety and efficacy profiles of existing immunomodulatory therapies.
Silverback’s pipeline includes multiple antibody-TLR agonist conjugates in early-phase clinical trials, each directed against distinct tumor-associated antigens.
See Also
- Five stocks we like better than Silverback Therapeutics
- AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
- Micron’s $250 Billion Bet Could Reshape the AI Memory Race
- Rocket Lab’s Stock Drop Comes With a Bullish Twist
- Amazon’s New Debt Deal Puts Its AI Spending Story on Trial
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
